


PHARMACEUTICAL 2022

Avalo Therapeutics Inc. Rank 396 of 466









PHARMACEUTICAL 2022

Avalo Therapeutics Inc. Rank 396 of 466



The relative strengths and weaknesses of Avalo Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Avalo Therapeutics Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 22% points. The greatest weakness of Avalo Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 70% points.

The company's Economic Capital Ratio, given in the ranking table, is -65%, being 143% points below the market average of 78%.

| Input Variable | Value in 1000 USD |
|---|----------------------|
| Assets, Current | 61,845 |
| Cost of Goods Sold | 1,491 |
| Intangible Assets | 14,447 |
| Liabilities, Current | 19,888 |
| Liabilities, Non-Current | 2,298 |
| Other Assets | 3,922 |
| Other Compr. Net Income | 0 |
| Other Expenses | 4,178 |
| Other Liabilities | 34,946 |
| Other Net Income | -2,438 |
| Other Revenues | 5,398 |
| Property and Equipment | 0 |
| Research and Development | 59,835 |
| Selling, General and Administrative Expense | 21,832 |

| Output Variable | Value in 1000 USD |
|--------------------------|----------------------|
| Assets | 80,214 |
| Liabilities | 57,132 |
| Expenses | 87,336 |
| Revenues | 5,398 |
| Stockholders Equity | 23,082 |
| Net Income | -84,376 |
| Comprehensive Net Income | -84,376 |
| Economic Capital Ratio | -65% |

